Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
mFOLFOX6 Variant #02 | — | R 2 466 | 14d | ~8.4 mo | ~12.7 mo | ~19 | ~R 46 863 PFS proxy · indirect | 15 |
Capecitabine monotherapy Variant #17 | — | R 2 219 | 21d | — | — | — | — | 1 |
FULV Variant #01 | — | R 1 466 | 35d | ~5.6 mo | ~13.1 mo | ~5 | ~R 7 330 PFS proxy · indirect | 15 |
Fluorouracil monotherapy Variant #16 | — | R 858 | 42d | — | — | — | — | 1 |
UFT monotherapy Variant #04 Partial | — | — | 28d | — | — | — | — | 1 |
S-1 monotherapy Variant #01 Partial | — | — | 21d | ~1.7 mo | ~10.5 mo | ~3 | — | 13 |
6 of 6 regimens shown